Shannon Turnbow, MD
Pulmonary Disease · Lubbock, TXNPI 1366444721
Payments from drug & device makers
Across 622 payments — averaging $34.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$12K
- GSK$4K
- Boehringer Ingelheim$1K
- Grifols USA, LLC$930
- Amgen$384
- Johnson & Johnson$354
- plus $4K from 30 others
What the payments were for
- Speaking & faculty fees$10,10047%
- Travel & lodging$2751%
- Food & beverage$11,30052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 71 | $11,684 |
| GSK | 219 | $3,585 |
| Boehringer Ingelheim | 61 | $1,127 |
| Grifols USA, LLC | 50 | $930 |
| Amgen | 22 | $384 |
| Johnson & Johnson | 19 | $354 |
| Actelion Pharmaceuticals US, Inc. | 18 | $301 |
| Baxter Healthcare | 15 | $281 |
| Regeneron Healthcare Solutions, Inc. | 13 | $268 |
| Sanofi | 13 | $251 |
| Mylan Specialty L.p. | 14 | $243 |
| Abiomed | 8 | $207 |
| Insmed, Inc. | 11 | $198 |
| Pfizer | 10 | $196 |
| United Therapeutics Corporation | 11 | $184 |
| UCB, Inc. | 4 | $182 |
| Verona Pharma, Inc. | 8 | $165 |
| AbbVie(2 entities) | 10 | $151 |
| Philips North America LLC | 3 | $147 |
| Shionogi Inc | 1 | $117 |
| Sanofi-aventis U.S. LLC | 6 | $93 |
| Sunovion Pharmaceuticals Inc. | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $78 |
| Genentech USA, Inc. | 4 | $76 |
| Merck | 5 | $69 |
| Gilead | 3 | $55 |
| Electromed, Inc. | 3 | $41 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Inogen, Inc. | 3 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Viatris Specialty LLC | 1 | $28 |
| Bayer | 1 | $22 |
| Boston Scientific | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$8,061
- BREZTRI AEROSPHERE$2,550
- SRC Und$118
- Fetroja$117
How this compares
$21,675 in reported general payments places this provider in the 80th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 17 | $229,558 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 211 | $185,124 |
| TezspireTezepelumab-Ekko | 11 | $70,915 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $43,330 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $41,276 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $30,521 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $27,104 |
| Spiriva RespimatTiotropium Bromide | 17 | $18,570 |
| EliquisApixaban | 14 | $8,647 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $8,305 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $7,803 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 161 | $5,631 |
| Budesonide | 15 | $5,237 |
| Wixela InhubFluticasone Propion/Salmeterol | 33 | $4,720 |
| Ventolin HfaAlbuterol Sulfate | 59 | $3,362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,127 | $283,03488 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $3,585 | $256,922334 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $11,684 | $114,24550 claims |
| PfizerEliquis | $196 | $8,64714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Lubbock
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.